These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
158 related articles for article (PubMed ID: 28221772)
1. Desleucyl-Oritavancin with a Damaged d-Ala-d-Ala Binding Site Inhibits the Transpeptidation Step of Cell-Wall Biosynthesis in Whole Cells of Staphylococcus aureus. Kim SJ; Singh M; Sharif S; Schaefer J Biochemistry; 2017 Mar; 56(10):1529-1535. PubMed ID: 28221772 [TBL] [Abstract][Full Text] [Related]
2. Inhibition of Staphylococcus aureus Cell Wall Biosynthesis by Desleucyl-Oritavancin: a Quantitative Peptidoglycan Composition Analysis by Mass Spectrometry. Chang JD; Foster EE; Thadani AN; Ramirez AJ; Kim SJ J Bacteriol; 2017 Aug; 199(15):. PubMed ID: 28507244 [TBL] [Abstract][Full Text] [Related]
3. Oritavancin exhibits dual mode of action to inhibit cell-wall biosynthesis in Staphylococcus aureus. Kim SJ; Cegelski L; Stueber D; Singh M; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J J Mol Biol; 2008 Mar; 377(1):281-93. PubMed ID: 18258256 [TBL] [Abstract][Full Text] [Related]
4. Structures of Staphylococcus aureus cell-wall complexes with vancomycin, eremomycin, and chloroeremomycin derivatives by 13C{19F} and 15N{19F} rotational-echo double resonance. Kim SJ; Cegelski L; Preobrazhenskaya M; Schaefer J Biochemistry; 2006 Apr; 45(16):5235-50. PubMed ID: 16618112 [TBL] [Abstract][Full Text] [Related]
5. Vancomycin and oritavancin have different modes of action in Enterococcus faecium. Patti GJ; Kim SJ; Yu TY; Dietrich E; Tanaka KS; Parr TR; Far AR; Schaefer J J Mol Biol; 2009 Oct; 392(5):1178-91. PubMed ID: 19576226 [TBL] [Abstract][Full Text] [Related]
6. Inhibition of d-Ala incorporation into wall teichoic acid in Staphylococcus aureus by desleucyl-oritavancin. Chang J; Coffman L; Kim SJ Chem Commun (Camb); 2017 May; 53(41):5649-5652. PubMed ID: 28480909 [TBL] [Abstract][Full Text] [Related]
7. Vancomycin derivative with damaged D-Ala-D-Ala binding cleft binds to cross-linked peptidoglycan in the cell wall of Staphylococcus aureus. Kim SJ; Matsuoka S; Patti GJ; Schaefer J Biochemistry; 2008 Mar; 47(12):3822-31. PubMed ID: 18302341 [TBL] [Abstract][Full Text] [Related]
8. Oritavancin binds to isolated protoplast membranes but not intact protoplasts of Staphylococcus aureus. Kim SJ; Singh M; Schaefer J J Mol Biol; 2009 Aug; 391(2):414-25. PubMed ID: 19538971 [TBL] [Abstract][Full Text] [Related]
9. Bacterial cell wall composition and the influence of antibiotics by cell-wall and whole-cell NMR. Romaniuk JA; Cegelski L Philos Trans R Soc Lond B Biol Sci; 2015 Oct; 370(1679):. PubMed ID: 26370936 [TBL] [Abstract][Full Text] [Related]
10. Structural variations of the cell wall precursor lipid II and their influence on binding and activity of the lipoglycopeptide antibiotic oritavancin. Münch D; Engels I; Müller A; Reder-Christ K; Falkenstein-Paul H; Bierbaum G; Grein F; Bendas G; Sahl HG; Schneider T Antimicrob Agents Chemother; 2015 Feb; 59(2):772-81. PubMed ID: 25403671 [TBL] [Abstract][Full Text] [Related]
11. Conformational and quantitative characterization of oritavancin-peptidoglycan complexes in whole cells of Staphylococcus aureus by in vivo 13C and 15N labeling. Cegelski L; Steuber D; Mehta AK; Kulp DW; Axelsen PH; Schaefer J J Mol Biol; 2006 Apr; 357(4):1253-62. PubMed ID: 16483598 [TBL] [Abstract][Full Text] [Related]
12. Characterization of the peptidoglycan of vancomycin-susceptible Enterococcus faecium. Patti GJ; Kim SJ; Schaefer J Biochemistry; 2008 Aug; 47(32):8378-85. PubMed ID: 18642854 [TBL] [Abstract][Full Text] [Related]
13. Hydrophobic side-chain length determines activity and conformational heterogeneity of a vancomycin derivative bound to the cell wall of Staphylococcus aureus. Kim SJ; Schaefer J Biochemistry; 2008 Sep; 47(38):10155-61. PubMed ID: 18759499 [TBL] [Abstract][Full Text] [Related]
14. Hidden Mode of Action of Glycopeptide Antibiotics: Inhibition of Wall Teichoic Acid Biosynthesis. Singh M; Chang J; Coffman L; Kim SJ J Phys Chem B; 2017 Apr; 121(16):3925-3932. PubMed ID: 28368603 [TBL] [Abstract][Full Text] [Related]
16. Oritavancin: mechanism of action. Zhanel GG; Schweizer F; Karlowsky JA Clin Infect Dis; 2012 Apr; 54 Suppl 3():S214-9. PubMed ID: 22431851 [TBL] [Abstract][Full Text] [Related]
17. The Carboxyl Terminus of Eremomycin Facilitates Binding to the Non-d-Ala-d-Ala Segment of the Peptidoglycan Pentapeptide Stem. Chang J; Zhou H; Preobrazhenskaya M; Tao P; Kim SJ Biochemistry; 2016 Jun; 55(24):3383-91. PubMed ID: 27243469 [TBL] [Abstract][Full Text] [Related]
18. Molecular modeling of Gram-positive bacteria peptidoglycan layer, selected glycopeptide antibiotics and vancomycin derivatives modified with sugar moieties. Ślusarz R; Szulc M; Madaj J Carbohydr Res; 2014 May; 389():154-64. PubMed ID: 24685455 [TBL] [Abstract][Full Text] [Related]
19. Quantification of the d-Ala-d-Lac-Terminated Peptidoglycan Structure in Vancomycin-Resistant Enterococcus faecalis Using a Combined Solid-State Nuclear Magnetic Resonance and Mass Spectrometry Analysis. Chang JD; Foster EE; Yang H; Kim SJ Biochemistry; 2017 Jan; 56(4):612-622. PubMed ID: 28040891 [TBL] [Abstract][Full Text] [Related]